Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy

Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jae Hee, Geum, Min Jung, Kang, Ji Eun, Park, Nam Gi, Oh, Yun Kyoung, Rhie, Sandy Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620630/
https://www.ncbi.nlm.nih.gov/pubmed/34832982
http://dx.doi.org/10.3390/ph14111200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620630/
https://www.ncbi.nlm.nih.gov/pubmed/34832982
http://dx.doi.org/10.3390/ph14111200

Ejemplares similares